People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GelMEDIX, Inc. | — | Biotechnology | Series A | $9.9M | $1.6M | 2020 |
| Siamab Therapeutics, Inc. | — | Biotechnology | Seed | $8.8M | $29.5M | 2012 |
| Savran Technologies Inc. | — | Biotechnology | Series A | $6.2M | $2.1M | 2021 |
Jeffrey Behrens at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Behrens on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sundar Subramaniam | 1 | 6 |
| Patrick Rivelli | 1 | 6 |
| Michael Cima | 1 | 4 |
| PARINAZ MOTAMEDY | 1 | 3 |
| PETER KROON | 1 | 3 |
| Reza Dana | 1 | 3 |
| Mark Carthy | 1 | 2 |
| Simon W. Turner | 1 | 2 |
| Mark Hattendorf | 1 | 2 |
| Gary Pforzheimer | 1 | 1 |
| Ajit Varki | 1 | 1 |
| Nasim Annabi | 1 | 1 |
| Max Cotler | 1 | 1 |
| Saleh W. Daher | 1 | 1 |
| Arthur Driscoll | 1 | 1 |
| Cagri Savran | 1 | 1 |
| Nadia Altomare | 1 | 1 |
| Sal Daher | 1 | 1 |
| Yavuz Kaynar | 1 | 1 |
| Jeff Behrens | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.